Publication & Citation Trends
Publications
0 total
Randomized Phase III SIERRA Trial of 131I-Apamistamab Before Allogeneic Hematopoietic Cell Transplantation Versus Conventional Care for Relapsed/Refractory AML
Cited by 11
Semantic Scholar
131I-Apamistamab Improves Outcomes in Patients 65 Years and Older with Relapsed or Refractory AML
Cited by 2
Semantic Scholar
AML-545 Long-Term Follow-up Demonstrates Ongoing Efficacy Benefit of 131I-Apamistamab-led Allogeneic Hematopoietic Cell Transplantation in Older Patients With Active, R/R AML in the Phase 3 SIERRA Trial
Cited by 0
Semantic Scholar
131I-Apamistamab-Led Allogeneic Hematopoietic Cell Transplant for Patients with TP53 Mutated R/R AML Results in Significantly Improved Outcomes
Cited by 0
Semantic Scholar
Final outcomes from a phase 2 trial of posoleucel in allogeneic hematopoietic cell transplant recipients OA
Cited by 15
Semantic Scholar
Targeted Myeloablative Radiation Using 131I-Apamistamab Prior to Allogeneic Hematopoietic Cell Transplant for Patients with R/R AML Results in Robust Engraftment
Cited by 0
Semantic Scholar
Dose-Response Demonstrated for Durable Complete Remission Following High-Dose Targeted Radiation with 131I-Apamistamab Prior to HCT in Patients with R/R AML
Cited by 0
Semantic Scholar
Research Topics
Multiple Myeloma Research and Treatments
(32)
Acute Myeloid Leukemia Research
(21)
Hematopoietic Stem Cell Transplantation
(19)
Nutrition and Health in Aging
(14)
Protein Degradation and Inhibitors
(13)
Affiliations
Kagoshima University
Atrium Health Wake Forest Baptist
Northwell Health
NewYork–Presbyterian Hospital
Harvard University